A blood protein links APOE4 gene to Alzheimer’s vessel damage

The blood-brain barrier is a tightly controlled boundary that prevents harmful substances in the bloodstream from entering brain tissue. In Alzheimer’s patients carrying the APOE4 gene variant, this barrier is compromised. The molecular link between the gene and that vascular damage had remained unclear until now.

Researchers identified fibronectin, a protein produced by brain support cells called astrocytes, as a key intermediary. The study shows that APOE4, in combination with amyloid pathology (the accumulation of protein fragments characteristic of Alzheimer’s), drives astrocytes to overproduce fibronectin. That excess fibronectin then damages the walls of blood vessels in and around the brain.

A missing link in the chain from gene to vessel damage

The APOE4 gene was already a well-established risk factor, and the role of amyloid in vascular damage had been described previously. What is new is that fibronectin (FN1) acts as the critical intermediate step. The protein binds to the inner lining of blood vessels and disrupts the normal function of the cells there.

The researchers suggest that FN1 is a potential therapeutic target. Whether inhibiting fibronectin reduces barrier damage in humans cannot yet be concluded from this study alone. The findings were published in Nature Aging and add a new dimension to understanding the vascular component of Alzheimer’s disease.

Why this matters for ageing research broadly

Blood vessel fragility in the brain is not unique to Alzheimer’s. The blood-brain barrier becomes more permeable with age even in people without dementia. The APOE4 connection makes this mechanism particularly relevant: an estimated 15 to 25 percent of the population carries at least one copy of this gene variant. A clearer understanding of how APOE4 drives damage via fibronectin could, in the longer term, inform preventive strategies for people with this genetic profile.

Read the original article